Literature DB >> 30639307

Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus.

Myung Hee Kim1, Jung-Ok Kang1, Joo-Young Kim1, Hi Eun Jung2, Heung Kyu Lee2, Jun Chang3.   

Abstract

Nucleoprotein is highly conserved among each type of influenza viruses (A and B) and has received significant attention as a good target for universal influenza vaccine. In this study, we determined whether a recombinant adenovirus encoding nucleoprotein of type B influenza virus (rAd/B-NP) confers protection against influenza virus infection in mice. We also identified a cytotoxic T lymphocyte epitope in the nucleoprotein to determine B-NP-specific CD8 T-cell responses. We found that B-NP-specific CD8 T cells induced by rAd/B-NP immunization played a major role in protection following influenza B virus infection using CD8 knockout mice. To assess the effects of the administration routes on protective immunity, we immunized mice with rAd/B-NP via intranasal or intramuscular routes. Both groups showed strong NP-specific humoral and CD8 T-cell responses, but only intranasal immunization provided complete protection against both lineages of influenza B virus challenge. Intranasal but not intramuscular administration established resident memory CD8 T cells in the airway and lung parenchyma, which were required for efficient protection. Furthermore, rAd/B-NP in combination with rAd/A-NP protected mice against lethal infection with both influenza A and B viruses. These findings demonstrate that rAd/B-NP could be further developed as a universal vaccine against influenza.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Influenza B virus; Mucosal immunization; Nucleoprotein; Protection; Vaccine

Mesh:

Substances:

Year:  2019        PMID: 30639307     DOI: 10.1016/j.antiviral.2019.01.002

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  12 in total

1.  Reduction of Influenza A Virus Transmission in Mice by a Universal Intranasal Vaccine Candidate is Long-Lasting and Does Not Require Antibodies.

Authors:  Graeme E Price; Chia-Yun Lo; Julia A Misplon; Suzanne L Epstein
Journal:  J Virol       Date:  2022-05-31       Impact factor: 6.549

Review 2.  Influenza B: Prospects for the Development of Cross-Protective Vaccines.

Authors:  Liudmila M Tsybalova; Liudmila A Stepanova; Edward S Ramsay; Andrey V Vasin
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

3.  Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus.

Authors:  So-Young Lee; Jung-Ok Kang; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2019-01-31

Review 4.  Adenovirus Vectors: Excellent Tools for Vaccine Development.

Authors:  Jun Chang
Journal:  Immune Netw       Date:  2021-02-15       Impact factor: 6.303

5.  Development of a Mouse Model to Explore CD4 T Cell Specificity, Phenotype, and Recruitment to the Lung after Influenza B Infection.

Authors:  Ajitanuj Rattan; Chantelle L White; Sean Nelson; Max Eismann; Herbey Padilla-Quirarte; Maryah A Glover; Thamotharampillai Dileepan; Bindumadhav M Marathe; Elena A Govorkova; Richard J Webby; Katherine A Richards; Andrea J Sant
Journal:  Pathogens       Date:  2022-02-15

6.  Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus.

Authors:  Hae-Ji Kang; Ki-Back Chu; Keon-Woong Yoon; Gi-Deok Eom; Jie Mao; Fu-Shi Quan
Journal:  Biomedicines       Date:  2022-07-06

7.  Invaplex functions as an intranasal adjuvant for subunit and DNA vaccines co-delivered in the nasal cavity of nonhuman primates.

Authors:  Jeremy V Camp; Robert L Wilson; Morgan Singletary; James L Blanchard; Anna Aldovini; Robert W Kaminski; Edwin V Oaks; Pamela A Kozlowski
Journal:  Vaccine X       Date:  2021-06-24

8.  Insights from the comparison of genomic variants from two influenza B viruses grown in the presence of human antibodies in cell culture.

Authors:  Ewan P Plant; Hasmik Manukyan; Majid Laassri; Zhiping Ye
Journal:  PLoS One       Date:  2020-09-14       Impact factor: 3.240

Review 9.  Progress in the Development of Universal Influenza Vaccines.

Authors:  Wenqiang Sun; Tingrong Luo; Wenjun Liu; Jing Li
Journal:  Viruses       Date:  2020-09-17       Impact factor: 5.048

Review 10.  The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses-Not Just Another Brick in the Viral Nucleocapsid.

Authors:  Maja Šantak; Zrinka Matić
Journal:  Viruses       Date:  2022-03-03       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.